You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live

2

1

▲  4th Inning 2 outs

Daily Dose

FDA approves first pill for pollen allergies

As the spring allergy season gets underway, a new pill to treat grass pollen allergies was approved this week by the US Food and Drug Administration. Oralair -- a once-daily tablet that rapidly dissolves after it is placed under the tongue -- treats sneezing, congestion, running nose, and itchy, watery eyes caused by hay fever.

It’s the first treatment made with an allergen extract that’s not a shot approved for use in the United States for allergy sufferers ages 10 through 65.

Continue reading below

The first dose needs to be given in a doctor’s office to determine if there are any allergic reactions, according to the FDA. People can take subsequent doses at home.

“While there is no cure for grass pollen allergies, they can be managed through treatment and avoiding exposure to the pollen,” Dr. Karen Midthun, director of the FDA’s Center for Biologics Evaluation and Research said in a statement. “The approval of Oralair provides an alternative to allergy shots that must be given in a health care provider’s office.”

Like allergy shots, Oralair should be started four months before the start of the grass pollen season -- which usually hits during the late spring -- and continued throughout the allergy season.

The FDA reviewed clinical trials involving about 2,500 people found that those who were treated with Oralair had a 16 to 30 percent reduction in their allergy symptoms compared to those given a placebo. The manufacturer didn’t compare, though, whether Oralair was as effective as allergy shots.

The drug contains warning about severe allergic reactions — such as life-threatening anaphylaxis — that can occur from the product. The most common side effects in adults were itching in the ears and mouth and on the tongue, as well as swelling of the mouth and throat irritation, according to the FDA. Children were most likely to experience itching and swelling in the mouth and throat irritation.

Deborah Kotz can be reached at dkotz@globe.com. Follow her on Twitter @debkotz2.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.